<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130883</url>
  </required_header>
  <id_info>
    <org_study_id>P12-109</org_study_id>
    <nct_id>NCT01130883</nct_id>
  </id_info>
  <brief_title>Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR</brief_title>
  <official_title>Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR in Patients With Upper Respiratory Infection, Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in the Czech Republic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post-marketing observational study (PMOS) will be conducted in a prospective,
      single-arm, single-country, multicenter format. The investigational sites will be consulting
      rooms of GPs (general practitioner), pneumologists and centers with experience in the
      treatment of patients with acute infections of trachea, bronchi, AECB (acute exacerbation of
      chronic bronchitis) and CAP (mild community-acquired pneumonia). Since this will be a
      post-marketing observational study, Klacid SR will be prescribed in usual manner in
      accordance with the terms of the local market authorization with regards to dose, population
      and indication as well as local guidelines. Objective: to describe the effectiveness of the
      treatment with repeated administration of Klacid SR in patients with acute tracheitis, acute
      tracheobronchitis or acute bronchitis; or in patients with acute exacerbation of chronic
      bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment
      6 weeks to 24 months prior to the Klacid SR dose administered within this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follow-up of participants should enable three visits during this period. At the Screening
      Visit the decision for Klacid SR therapy in a dose of 500 -1000 mg once daily will be made.
      The Second Visit will occur 8 - 16 days after study initiation. The Last Visit will be a
      phone call to the participant after 30 days from the initiation of the treatment. Study
      visits will be defined as &quot;V1&quot; = Screening Visit, &quot;V2&quot; = Visit in which Klacid SR therapy
      will be terminated and &quot;V3&quot; = Phone call 30 days after initiation of Klacid SR therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disappearance or Significant Alleviation of Symptoms</measure>
    <time_frame>Day 8 - 16</time_frame>
    <description>Overall therapeutic response, &quot;yes&quot; or &quot;no&quot; was determined by the physician based on subjective response regarding disappearance or significant alleviation of symptoms following treatment. The physician also considered objective findings such as auscultation and or chest X-ray results (if available) when determining overall therapeutic response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Auscultation Findings, Regression of Chest X-ray Findings (Recorded by the Physician)</measure>
    <time_frame>Day 0, Day 8 - 16</time_frame>
    <description>Auscultation findings (abnormal breath sounds) were assessed at the initial visit (Day 0) and the second visit (Day 8 -16) by the physician. &quot;Regression of chest X-ray findings&quot; were not recorded as it is not part of routine clinical practice to confirm X-ray regression after the participant has clinically recovered from Community-Acquired Pneumonia (CAP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Day 0, Day 8-16</time_frame>
    <description>Number of participants in which body temperature was increased (temperature above 37 degrees Celsius).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriological Investigation (if Available)</measure>
    <time_frame>Day 0</time_frame>
    <description>The type of agent present in the infection was assessed using bacteriological investigation. Occurrence of the most common agents was reported. Participants may have had more than one pathogen present. Test results were not available prior to enrollment but were reported during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough and Its Character</measure>
    <time_frame>Day 0, Day 8-16</time_frame>
    <description>Number of participants in which cough was present, and if present, type of cough (irritating, productive, both or not reported)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea and Its Type</measure>
    <time_frame>Day 0, Day 8-16</time_frame>
    <description>Presence of dyspnea (difficulty breathing) and type of dyspnea (exertional, resting, both, or not reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Auscultation</measure>
    <time_frame>Day 0, Day 8-16</time_frame>
    <description>Participants with abnormal auscultation findings (abnormal breath sounds) and type of findings (wheezing, crackles, both, or not reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest X-ray in Case of Community-Acquired Pneumonia (CAP)</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of participants in which X-ray findings were suggestive of pneumonia. In participants where the physician suspected CAP, a chest X-ray was performed and reviewed to determine whether findings were indicative of pneumonia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Drug Given as the First, Second or Third Antimicrobial Treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of participants who received Klacid SR as the first, second or third (further) antimicrobial agent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Day 8 - 16</time_frame>
    <description>Number of participants who took their medication according to the prescribed regimen (dose and duration) during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Termination of Treatment Due to Noncompliance</measure>
    <time_frame>Day 8 - 16</time_frame>
    <description>Number of participants who discontinued Klacid SR treatment early due to noncompliance with the recommended study medication regimen.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3130</enrollment>
  <condition>Tracheitis</condition>
  <condition>Tracheobronchitis</condition>
  <condition>Bronchitis</condition>
  <condition>Chronic Bronchitis</condition>
  <condition>Community-Acquired Pneumonia (CAP)</condition>
  <arm_group>
    <arm_group_label>Respiratory Infections</arm_group_label>
    <description>Czech patients with acute tracheitis, acute tracheobronchitis or acute bronchitis; or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid®SR treatment 6 weeks prior to the next Klacid®SR dose or in intervals: 7-week - 3- month, 4- month - 12- month, 13- month - 24- month prior to the next Klacid®SR dose (next Klacid®SR dose = dose administered within this PMOS).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with: acute tracheitis, acute tracheobronchitis or acute bronchitis, acute
        exacerbation of chronic bronchitis, mild community-acquired pneumonia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men, women at least 18 years old.

          -  Patients treated with Klacid®SR between 6 weeks and 24 months prior to start of the
             PMOS.

          -  Patients:

               -  with acute tracheitis,

               -  acute tracheobronchitis,

               -  acute bronchitis,

               -  mild community-acquired pneumonia or

               -  acute exacerbation of chronic bronchitis

        Exclusion Criteria:

          -  Patients without previous administration of Klacid®SR and patients who used Klacid®SR
             less than 6 weeks ago or more than 24 months ago. The information about previous
             administration of Klacid®SR will be based on physician records or patients anamnesis.

          -  Patients with known hypersensitivity to macrolide antibiotics

          -  Patients with documented renal impairment (creatinine clearance under 30 ml/min).

          -  Patients with documented liver parenchyma impairment (AST, ALT and GMT &gt; 3x higher
             level in comparison with the norm)

          -  Concomitant therapy with the following drugs: astemizole, cisapride, colchicine,
             pimozide, terfenadine and ergotamine or dihydroergotamine

          -  Pregnancy

          -  Breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Hloska, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Laboratories, s.r.o. (Czech Republic)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37381</name>
      <address>
        <city>Bilina</city>
        <zip>418 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37391</name>
      <address>
        <city>Bilina</city>
        <zip>418 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37282</name>
      <address>
        <city>Blansko</city>
        <zip>678 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37324</name>
      <address>
        <city>Blansko</city>
        <zip>678 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37424</name>
      <address>
        <city>Boskovice</city>
        <zip>680 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37329</name>
      <address>
        <city>Brandys nad Labem</city>
        <zip>250 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37443</name>
      <address>
        <city>Breclav</city>
        <zip>690 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37268</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37299</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37331</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37396</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37411</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37403</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37380</name>
      <address>
        <city>Brno</city>
        <zip>616 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37327</name>
      <address>
        <city>Brno</city>
        <zip>636 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37429</name>
      <address>
        <city>Bucovice</city>
        <zip>685 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37444</name>
      <address>
        <city>Bucovice</city>
        <zip>685 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37298</name>
      <address>
        <city>Budweis</city>
        <zip>370 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37433</name>
      <address>
        <city>Bustehrad</city>
        <zip>273 43</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37374</name>
      <address>
        <city>Caslav</city>
        <zip>286 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37267</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37269</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37302</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37392</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37408</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 87</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37362</name>
      <address>
        <city>Cheb</city>
        <zip>350 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47286</name>
      <address>
        <city>Cheb</city>
        <zip>35002</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37413</name>
      <address>
        <city>Chrudim</city>
        <zip>537 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37372</name>
      <address>
        <city>Decin</city>
        <zip>405 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37394</name>
      <address>
        <city>Decin</city>
        <zip>40501</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 26623</name>
      <address>
        <city>Hardec Kralove</city>
        <zip>500 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37270</name>
      <address>
        <city>Hardec Kralove</city>
        <zip>500 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37371</name>
      <address>
        <city>Hardec Kralove</city>
        <zip>500 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43225</name>
      <address>
        <city>Hardec Kralove</city>
        <zip>500 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37263</name>
      <address>
        <city>Holesov</city>
        <zip>769 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43230</name>
      <address>
        <city>Holesov</city>
        <zip>769 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37274</name>
      <address>
        <city>Hradek</city>
        <zip>338 42</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37367</name>
      <address>
        <city>Hranice</city>
        <zip>753 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37364</name>
      <address>
        <city>Hrebec</city>
        <zip>273 45</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37404</name>
      <address>
        <city>Jablonec nad Nisou</city>
        <zip>466 04</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47283</name>
      <address>
        <city>Jablonec nad Nisou</city>
        <zip>468 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43229</name>
      <address>
        <city>Jaromer</city>
        <zip>551 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37376</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37290</name>
      <address>
        <city>Kaplice</city>
        <zip>382 41</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37369</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>360 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37445</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>360 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37363</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>360 17</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37283</name>
      <address>
        <city>Kladno</city>
        <zip>272 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37382</name>
      <address>
        <city>Kolin</city>
        <zip>280 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37368</name>
      <address>
        <city>Konice</city>
        <zip>798 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37415</name>
      <address>
        <city>Konice</city>
        <zip>798 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37272</name>
      <address>
        <city>Kralovice</city>
        <zip>331 41</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42162</name>
      <address>
        <city>Kunovice</city>
        <zip>68604</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43224</name>
      <address>
        <city>Kyjov</city>
        <zip>697 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37323</name>
      <address>
        <city>Letohrad</city>
        <zip>561 51</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37389</name>
      <address>
        <city>Liberec</city>
        <zip>460 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37416</name>
      <address>
        <city>Litomysl</city>
        <zip>570 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37384</name>
      <address>
        <city>Litvinov</city>
        <zip>43542</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37428</name>
      <address>
        <city>Marianske Lazne</city>
        <zip>353 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37289</name>
      <address>
        <city>Melnik</city>
        <zip>276 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37293</name>
      <address>
        <city>Mestec Kralove</city>
        <zip>289 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43228</name>
      <address>
        <city>Mohelnice</city>
        <zip>78985</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43233</name>
      <address>
        <city>Mohelnice</city>
        <zip>78985</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43227</name>
      <address>
        <city>Moravska Trebova</city>
        <zip>571 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47290</name>
      <address>
        <city>Most</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37297</name>
      <address>
        <city>Neratovice</city>
        <zip>277 11</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37397</name>
      <address>
        <city>Novy Bor</city>
        <zip>473 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37303</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37400</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37399</name>
      <address>
        <city>Obristvi</city>
        <zip>277 42</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37279</name>
      <address>
        <city>Olomouc</city>
        <zip>772 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37280</name>
      <address>
        <city>Olomouc</city>
        <zip>772 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37395</name>
      <address>
        <city>Pardubice</city>
        <zip>530 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47284</name>
      <address>
        <city>Plana</city>
        <zip>348 15</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37271</name>
      <address>
        <city>Plzen</city>
        <zip>301 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37273</name>
      <address>
        <city>Plzen</city>
        <zip>304 11</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37423</name>
      <address>
        <city>Plzen</city>
        <zip>323 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37431</name>
      <address>
        <city>Plzen</city>
        <zip>326 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37325</name>
      <address>
        <city>Podebrady</city>
        <zip>290 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47282</name>
      <address>
        <city>Podebrady</city>
        <zip>290 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37375</name>
      <address>
        <city>Prague 10</city>
        <zip>100 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37294</name>
      <address>
        <city>Prague 14</city>
        <zip>198 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37328</name>
      <address>
        <city>Prague 1</city>
        <zip>141 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37398</name>
      <address>
        <city>Prague 2</city>
        <zip>120 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37410</name>
      <address>
        <city>Prague 3</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37387</name>
      <address>
        <city>Prague 4</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37390</name>
      <address>
        <city>Prague 4</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43232</name>
      <address>
        <city>Prague 4</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43365</name>
      <address>
        <city>Prague 4</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43236</name>
      <address>
        <city>Prague 4</city>
        <zip>142 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37295</name>
      <address>
        <city>Prague 5</city>
        <zip>150 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37427</name>
      <address>
        <city>Prague 5</city>
        <zip>158 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37419</name>
      <address>
        <city>Prague 6</city>
        <zip>163 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37438</name>
      <address>
        <city>Prague 6</city>
        <zip>169 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37414</name>
      <address>
        <city>Prague 9</city>
        <zip>190 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47289</name>
      <address>
        <city>Prague 9</city>
        <zip>190 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37288</name>
      <address>
        <city>Prague</city>
        <zip>141 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37300</name>
      <address>
        <city>Prague</city>
        <zip>141 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37301</name>
      <address>
        <city>Prague</city>
        <zip>141 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37330</name>
      <address>
        <city>Prague</city>
        <zip>141 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37332</name>
      <address>
        <city>Prague</city>
        <zip>141 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37262</name>
      <address>
        <city>Prague</city>
        <zip>149 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37275</name>
      <address>
        <city>Prague</city>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37326</name>
      <address>
        <city>Prague</city>
        <zip>181 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37291</name>
      <address>
        <city>Prague</city>
        <zip>198 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37378</name>
      <address>
        <city>Pribor</city>
        <zip>742 58</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37412</name>
      <address>
        <city>Pribor</city>
        <zip>742 58</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37432</name>
      <address>
        <city>Pribram</city>
        <zip>261 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37425</name>
      <address>
        <city>Pribram</city>
        <zip>261 95</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37437</name>
      <address>
        <city>Prostejov</city>
        <zip>796 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37430</name>
      <address>
        <city>Prostejov</city>
        <zip>796 04</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37442</name>
      <address>
        <city>Rakovnik</city>
        <zip>269 29</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37393</name>
      <address>
        <city>Raspenava</city>
        <zip>464 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37421</name>
      <address>
        <city>Roznov pod Radhostem</city>
        <zip>756 61</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37287</name>
      <address>
        <city>Sadova</city>
        <zip>612 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37406</name>
      <address>
        <city>Slapanice</city>
        <zip>664 51</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37383</name>
      <address>
        <city>Steti</city>
        <zip>41108</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37278</name>
      <address>
        <city>Sumperk</city>
        <zip>787 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43223</name>
      <address>
        <city>Sumperk</city>
        <zip>78701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43234</name>
      <address>
        <city>Sumperk</city>
        <zip>78752</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37285</name>
      <address>
        <city>Tachov</city>
        <zip>347 42</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37386</name>
      <address>
        <city>Teplice</city>
        <zip>415 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37264</name>
      <address>
        <city>Trebic</city>
        <zip>674 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37277</name>
      <address>
        <city>Trebic</city>
        <zip>674 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43231</name>
      <address>
        <city>Trebon</city>
        <zip>379 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37405</name>
      <address>
        <city>Trinec</city>
        <zip>739 61</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37265</name>
      <address>
        <city>Tyn nad Vltavou</city>
        <zip>375 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43366</name>
      <address>
        <city>Tyn</city>
        <zip>375 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37434</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37365</name>
      <address>
        <city>Uhersky Brod</city>
        <zip>688 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37284</name>
      <address>
        <city>Velke Pavlovice</city>
        <zip>691 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37385</name>
      <address>
        <city>Vlasim</city>
        <zip>258 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37322</name>
      <address>
        <city>Zamberk</city>
        <zip>56421</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37366</name>
      <address>
        <city>Zdar nad Sazavou</city>
        <zip>591 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43235</name>
      <address>
        <city>Zlin</city>
        <zip>762 75</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <results_first_submitted>July 25, 2011</results_first_submitted>
  <results_first_submitted_qc>July 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2011</results_first_posted>
  <last_update_submitted>September 8, 2011</last_update_submitted>
  <last_update_submitted_qc>September 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute tracheitis</keyword>
  <keyword>acute tracheobronchitis or acute bronchitis</keyword>
  <keyword>acute exacerbation of chronic bronchitis</keyword>
  <keyword>mild community-acquired pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Tracheitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Klacid SR Treatment</title>
          <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Analyzed</title>
              <participants_list>
                <participants group_id="P1" count="3128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Unknown</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Klacid SR Treatment</title>
          <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>less than 18 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 to 29 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to 39 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 49 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to 59 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 to 69 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 to 79 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 to 89 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 years of age and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Gender was not reported in this study.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disappearance or Significant Alleviation of Symptoms</title>
        <description>Overall therapeutic response, &quot;yes&quot; or &quot;no&quot; was determined by the physician based on subjective response regarding disappearance or significant alleviation of symptoms following treatment. The physician also considered objective findings such as auscultation and or chest X-ray results (if available) when determining overall therapeutic response.</description>
        <time_frame>Day 8 - 16</time_frame>
        <population>A total of 3130 participants were enrolled into the study and 3128 were included in the analysis. Two participants were excluded from the analysis as they did not meet entry criteria (2 participants were less than 18 years of age).</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR Treatment</title>
            <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Disappearance or Significant Alleviation of Symptoms</title>
          <description>Overall therapeutic response, &quot;yes&quot; or &quot;no&quot; was determined by the physician based on subjective response regarding disappearance or significant alleviation of symptoms following treatment. The physician also considered objective findings such as auscultation and or chest X-ray results (if available) when determining overall therapeutic response.</description>
          <population>A total of 3130 participants were enrolled into the study and 3128 were included in the analysis. Two participants were excluded from the analysis as they did not meet entry criteria (2 participants were less than 18 years of age).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Auscultation Findings, Regression of Chest X-ray Findings (Recorded by the Physician)</title>
        <description>Auscultation findings (abnormal breath sounds) were assessed at the initial visit (Day 0) and the second visit (Day 8 -16) by the physician. “Regression of chest X-ray findings” were not recorded as it is not part of routine clinical practice to confirm X-ray regression after the participant has clinically recovered from Community-Acquired Pneumonia (CAP).</description>
        <time_frame>Day 0, Day 8 - 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR Treatment</title>
            <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Auscultation Findings, Regression of Chest X-ray Findings (Recorded by the Physician)</title>
          <description>Auscultation findings (abnormal breath sounds) were assessed at the initial visit (Day 0) and the second visit (Day 8 -16) by the physician. “Regression of chest X-ray findings” were not recorded as it is not part of routine clinical practice to confirm X-ray regression after the participant has clinically recovered from Community-Acquired Pneumonia (CAP).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial Visit - Auscultation Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial Visit - Auscultation Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial Visit - Findings Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Visit - Auscultation Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Visit - Auscultation Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Visit - Findings Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Temperature</title>
        <description>Number of participants in which body temperature was increased (temperature above 37 degrees Celsius).</description>
        <time_frame>Day 0, Day 8-16</time_frame>
        <population>Of the 3128 participants included in the analysis, body temperature was not reported for 6 participants at the Initial visit, and 14 participants at the Second visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR Treatment</title>
            <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature</title>
          <description>Number of participants in which body temperature was increased (temperature above 37 degrees Celsius).</description>
          <population>Of the 3128 participants included in the analysis, body temperature was not reported for 6 participants at the Initial visit, and 14 participants at the Second visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial Visit - Temperature above 37 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial Visit - Temperature not above 37 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial Visit - Temperature not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Visit - Temperature above 37 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Visit - Temperature not above 37 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Visit - Temperature not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bacteriological Investigation (if Available)</title>
        <description>The type of agent present in the infection was assessed using bacteriological investigation. Occurrence of the most common agents was reported. Participants may have had more than one pathogen present. Test results were not available prior to enrollment but were reported during the study.</description>
        <time_frame>Day 0</time_frame>
        <population>Of the 3128 participants included in the analysis, 225 participants had bacteriological investigations conducted at the Initial visit (Day 0). Some participants had more than one finding.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR Treatment</title>
            <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacteriological Investigation (if Available)</title>
          <description>The type of agent present in the infection was assessed using bacteriological investigation. Occurrence of the most common agents was reported. Participants may have had more than one pathogen present. Test results were not available prior to enrollment but were reported during the study.</description>
          <population>Of the 3128 participants included in the analysis, 225 participants had bacteriological investigations conducted at the Initial visit (Day 0). Some participants had more than one finding.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Haemophilus Influenzae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chlamydia pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycoplasma pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus parainfluenzae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus species</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staphylococcus aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Branhamella catarrhalis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cough and Its Character</title>
        <description>Number of participants in which cough was present, and if present, type of cough (irritating, productive, both or not reported)</description>
        <time_frame>Day 0, Day 8-16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR Treatment</title>
            <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Cough and Its Character</title>
          <description>Number of participants in which cough was present, and if present, type of cough (irritating, productive, both or not reported)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial Visit - Presence of cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Irritating cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Productive cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>c) Both irritating and productive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>d) Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial Visit - Cough not present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Visit - Presence of cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Irritating cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Productive cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>c) Both irritating and productive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>d) Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Visit - Cough not present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea and Its Type</title>
        <description>Presence of dyspnea (difficulty breathing) and type of dyspnea (exertional, resting, both, or not reported).</description>
        <time_frame>Day 0, Day 8-16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR Treatment</title>
            <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea and Its Type</title>
          <description>Presence of dyspnea (difficulty breathing) and type of dyspnea (exertional, resting, both, or not reported).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial Visit - Presence of dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Exertional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Resting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>c) Both exertional and resting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>d) Type of dyspnea not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial Visit - Dyspnea not present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Visit - Presence of dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Exertional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Resting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>c) Both exertional and resting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>d) Type of dyspnea not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Visit - Dyspnea not present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Auscultation</title>
        <description>Participants with abnormal auscultation findings (abnormal breath sounds) and type of findings (wheezing, crackles, both, or not reported).</description>
        <time_frame>Day 0, Day 8-16</time_frame>
        <population>Of the 3128 participants included in the analysis, auscultation findings were not reported for 38 participants at the initial visit and 116 participants at the final visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR Treatment</title>
            <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Auscultation</title>
          <description>Participants with abnormal auscultation findings (abnormal breath sounds) and type of findings (wheezing, crackles, both, or not reported).</description>
          <population>Of the 3128 participants included in the analysis, auscultation findings were not reported for 38 participants at the initial visit and 116 participants at the final visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial Visit - Abnormal Auscultaton findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Crackles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>c) Both wheezing and crackles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>d) Not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Visit - Abnormal Auscultation findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Crackles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>c) Both wheezing and crackles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>d) Not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chest X-ray in Case of Community-Acquired Pneumonia (CAP)</title>
        <description>Number of participants in which X-ray findings were suggestive of pneumonia. In participants where the physician suspected CAP, a chest X-ray was performed and reviewed to determine whether findings were indicative of pneumonia.</description>
        <time_frame>Day 0</time_frame>
        <population>Chest X-ray was performed in 294 of the participants for whom the physician suspected pneumonia.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR Treatment</title>
            <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Chest X-ray in Case of Community-Acquired Pneumonia (CAP)</title>
          <description>Number of participants in which X-ray findings were suggestive of pneumonia. In participants where the physician suspected CAP, a chest X-ray was performed and reviewed to determine whether findings were indicative of pneumonia.</description>
          <population>Chest X-ray was performed in 294 of the participants for whom the physician suspected pneumonia.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Findings indicative of pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Findings not indicative of pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Drug Given as the First, Second or Third Antimicrobial Treatment</title>
        <description>Number of participants who received Klacid SR as the first, second or third (further) antimicrobial agent.</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR Treatment</title>
            <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Drug Given as the First, Second or Third Antimicrobial Treatment</title>
          <description>Number of participants who received Klacid SR as the first, second or third (further) antimicrobial agent.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Klacid SR as first antimicrobial treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klacid SR as second antimicrobial treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klacid SR as third antimicrobial treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance</title>
        <description>Number of participants who took their medication according to the prescribed regimen (dose and duration) during the study.</description>
        <time_frame>Day 8 - 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR Treatment</title>
            <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance</title>
          <description>Number of participants who took their medication according to the prescribed regimen (dose and duration) during the study.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Termination of Treatment Due to Noncompliance</title>
        <description>Number of participants who discontinued Klacid SR treatment early due to noncompliance with the recommended study medication regimen.</description>
        <time_frame>Day 8 - 16</time_frame>
        <population>A total of 3128 participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR Treatment</title>
            <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Termination of Treatment Due to Noncompliance</title>
          <description>Number of participants who discontinued Klacid SR treatment early due to noncompliance with the recommended study medication regimen.</description>
          <population>A total of 3128 participants were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the start to the completion of treatment with Klacid SR (8 to 16 days). Serious adverse events and relapse were reported for up to 30 days after the initiation of physician prescribed study treatment.</time_frame>
      <desc>Investigator monitored study participants for adverse events as per usual practice.</desc>
      <group_list>
        <group group_id="E1">
          <title>Klacid SR Treatment</title>
          <description>Adult Czech participants with acute tracheitis, acute tracheobronchitis or acute bronchitis; or participants with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose dose administered within this study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tuberculosis pleuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 13.1">Pulmonary tumor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bad taste in mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3128"/>
              </event>
              <event>
                <sub_title>Burning tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3128"/>
              </event>
              <event>
                <sub_title>Bitter taste in mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3128"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3128"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3128"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3128"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3128"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

